Su Hwan Kang
Overview
Explore the profile of Su Hwan Kang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
46
Citations
469
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lee Y, Noh W, Gwark S, Kim H, Ryu J, Kim S, et al.
Breast Cancer Res
. 2024 Nov;
26(1):152.
PMID: 39501399
Background: Chemo-endocrine therapy can lead to various side effects associated with ovarian dysfunction. Predicting menstrual recovery is necessary to discuss the treatment-related issues regarding fertility and premature menopause with patients....
2.
Bae S, Kim H, Kim H, Ryu J, Park S, Lee E, et al.
Int J Surg
. 2023 Nov;
110(2):934-942.
PMID: 38000057
Background: While the relationship between mammographic breast density reduction (MDR) and endocrine therapy efficacy has been reported in estrogen receptor (ER)-positive breast cancer, it is still unclear in premenopausal women,...
3.
Jeon C, Kang S, Kim S, Paik N, Lee I, Kim S, et al.
Oncology
. 2023 Oct;
102(6):465-475.
PMID: 37899039
Introduction: SB3 is a trastuzumab biosimilar approved in Australia, Brazil, Canada, the European Union, the Republic of Korea, Switzerland, and the USA. This real-world study evaluated safety and effectiveness of...
4.
Lee A, Kang T, Kang S, Park W, Lim W, Chang M, et al.
Breast
. 2023 Oct;
72:103585.
PMID: 37802015
Purpose: Pegfilgrastim is a widely used long-acting granulocyte colony-stimulating factor (G-CSF) that prevents febrile neutropenia (FN) in patients with breast cancer receiving chemotherapy. This study aimed to evaluate the incidence...
5.
Baek S, Noh W, Ahn S, Kim H, Ryu J, Kim S, et al.
J Clin Oncol
. 2023 Aug;
41(31):4864-4871.
PMID: 37607321
Purpose: To determine the updated long-term outcomes of the Addition of Ovarian Suppression to Tamoxifen in Young Women With Hormone-Sensitive Breast Cancer Who Remain Premenopausal or Regain Vaginal Bleeding After...
6.
Kim M, Kwon S, Choi J, Kang S, Bae Y
J Breast Cancer
. 2023 Apr;
26(2):105-116.
PMID: 37095618
Purpose: Oncotype DX (ODX) is a well-validated multigene assay that is increasingly used in Korean clinical practice. This study aimed to develop a clinicopathological prediction (CPP) model for the ODX...
7.
Paik H, Kim S, Kim K, Kim Y, Lee S, Kang S, et al.
BMC Cancer
. 2022 Dec;
22(1):1261.
PMID: 36471272
Background: Women from Asian and western countries have vastly different ages of onset of breast cancer, with the disease tending to occur at an older age in the West. Through...
8.
Kang J, Choi J, Kang S
World J Surg Oncol
. 2022 Sep;
20(1):327.
PMID: 36180912
Background: Papillary thyroid carcinoma (PTC) is the most common type of thyroid cancer, and its incidence has increased. Lateral lymph node metastasis (LLNM) implies a worse prognosis than central lymph...
9.
Kim M, Park M, Choi J, Kang S, Bae Y
J Breast Cancer
. 2022 Aug;
25(4):318-326.
PMID: 35914748
Purpose: The updated American Society of Clinical Oncology/College of American Pathologists guideline for estrogen receptor (ER) testing recommends that breast cancer with ER expression in 1-10% of tumor cells should...
10.
Lee J, Lee K, Sim S, Chae H, Sohn J, Kim G, et al.
Cancer Res Treat
. 2022 Mar;
55(1):123-135.
PMID: 35344650
Purpose: The treatment of male breast cancer (MBC) has been extrapolated from female breast cancer (FBC) because of its rarity despite their different clinicopathologic characteristics. We aimed to investigate the...